West Pharma CTO Silji Abraham resigns effective Dec 31, 2024

WEST PHARMACEUTICAL SERVICES INC

Silji Abraham, SVP & Chief Technology Officer, notified resignation on Oct 1, 2024.
Departure effective December 31, 2024; he leaves to pursue other interests.
Company states departure is not due to any disagreement on operations, policies, or practices.
No additional compensation or severance will be provided in connection with the resignation.
Transition plan involves working with Abraham and his leadership team to ensure smooth handover.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Silji Abraham

Senior Vice President & Chief Technology Officer

WST · WEST PHARMACEUTICAL SERVICES INC

Effective: 2024-12-31
Filed: October 7, 2024, 7:59 PM ET

On October 1, 2024, Silji Abraham, Senior Vice President & Chief Technology Officer of West Pharmaceutical Services, Inc. (the “Company”), notified the Company that he intends to resign, effective December 31, 2024, to pursue other interests.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Silji Abraham resigned as Senior Vice President & Chief Technology Officer at WEST PHARMACEUTICAL SERVICES INC.

Action: resigned
Role: Senior Vice President & Chief Technology Officer

Exact text from the filing

On October 1, 2024, Silji Abraham, Senior Vice President & Chief Technology Officer of West Pharmaceutical Services, Inc. (the “Company”), notified the Company that he intends to resign, effective December 31, 2024, to pursue other interests.

View on SEC.gov

WEST PHARMACEUTICAL SERVICES INC filing history →

Source: SEC EDGAR

accession 0000105770-24-000071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.